{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:45:38Z","timestamp":1776660338595,"version":"3.51.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Locally advanced prostate cancer (clinical stage T3 or higher) causes significant harm to patients, including decreased quality of life, high mortality rates, and economic burden. Current multimodal management for locally advanced prostate cancer often includes radiotherapy combined with long-term androgen deprivation therapy (ADT), with radical prostatectomy (RP) reserved for selected patients. However, RP alone or with ADT has limitations such as high biochemical recurrence rates and high positive surgical margin (PSM) rates. Therefore, this study aims to explore new effective treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched PubMed, Embase, Web of Science and Cochrane databases up of August 19, 2025. We analyzed data from 10 studies. The main outcomes assessed included biochemical progression-free survival (BPFS), PSM rate, overall survival (OS) and metastasis-free survival (MFS). We pooled risk ratios (RR) with 95% confidence intervals (CI) using fixed- or random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results show that compared with RP alone, the combination of NCHT and RP significantly improved BPFS (RR\u00a0=\u00a00.60, 95% CI: 0.41-0.87, P\u00a0=\u00a00.008), despite significant heterogeneity (I\u00b2 = 90%). In RCT subgroup analysis, the benefit remained significant (RR\u00a0=\u00a00.73, 95% CI: 0.62\u20130.86; P\u00a0=\u00a00.0002; I\u00b2 = 0%). The NCHT+RP group also showed a significant reduction in PSM rate (RR\u00a0=\u00a00.49, 95% CI: 0.37-0.65, P &amp;lt; 0.00001). For OS, the pooled analysis showed an improvement (RR\u00a0=\u00a00.45, 95% CI: 0.24-0.84, P\u00a0=\u00a00.01); however, this effect was entirely driven by non-randomized studies (RR\u00a0=\u00a00.55, 95% CI: 0.31\u20130.99; P\u00a0=\u00a00.04), while the randomized controlled trials (RCT) subgroup did not confirm a significant benefit (RR\u00a0=\u00a00.43, 95% CI: 0.10-1.88, P\u00a0=\u00a00.26). No significant improvement was observed in MFS (RR\u00a0=\u00a00.82, 95% CI: 0.45-1.49, P\u00a0=\u00a00.51), although the single large RCT (Eastham et\u00a0al.) favored NCHT+RP (RR\u00a0=\u00a00.78, 95% CI: 0.63\u20130.98; P\u00a0=\u00a00.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In selected patients with locally advanced prostate cancer, NCHT combined with RP may improve BPFS and reduce PSM rates, with the BPFS benefit confirmed in the RCT subgroup. However, the apparent OS benefit was not observed in RCTs and likely reflects bias in observational studies. According to GRADE, the certainty of evidence for survival outcomes is very low. These positive findings should be interpreted with caution, and adequately powered RCT with modern agents are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1693222","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:14:28Z","timestamp":1776658468000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of neoadjuvant chemohormonal therapy in combination with radical prostatectomy for locally advanced prostate cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Hua","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Urology, Deyang Hospital of Sichuan Provincial People\u2019s Hospital","place":["Deyang, China"]},{"name":"Department of Urology, Deyang Second People\u2019s Hospital","place":["Sichuan, Deyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Deyang Hospital of Sichuan Provincial People\u2019s Hospital","place":["Deyang, China"]},{"name":"Department of Urology, Deyang Second People\u2019s Hospital","place":["Sichuan, Deyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Deyang Hospital of Sichuan Provincial People\u2019s Hospital","place":["Deyang, China"]},{"name":"Department of Urology, Deyang Second People\u2019s Hospital","place":["Sichuan, Deyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2016.17.3.1187","article-title":"Predictors of positive bone metastasis in newly diagnosed prostate cancer patients","volume":"17","author":"Chien","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1300\/J077v24n02_04","article-title":"Health-related quality of life in Dutch men with prostate cancer","volume":"24","author":"Voerman","year":"2006","journal-title":"J Psychosoc Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020178","article-title":"Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis","volume":"30","author":"Berenguer","year":"2023","journal-title":"Curr Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0448-6","article-title":"Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada","volume":"19","author":"Smith-Palmer","year":"2019","journal-title":"BMC Urol"},{"key":"B5","article-title":"Radical radiotherapy for prostate cancer is the 'only way to go'","volume":"23","author":"Sandler","year":"2009","journal-title":"Oncol (Williston Park)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.11.020","article-title":"Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer","volume":"33","author":"EK","year":"2015","journal-title":"Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.6440","article-title":"Systematic review and meta-analysis of trials evaluating the role of adjuvant radiation after radical prostatectomy for prostate cancer: implications for early salvage","volume":"14","author":"Bhindi","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1093759","article-title":"Efficacy and safety of salvage radiotherapy combined with endocrine therapy in patients with biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Liang","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_96_20","article-title":"Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Liu","year":"2021","journal-title":"Asian J Androl"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The Prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Bmj"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12676","article-title":"Long term oncologic outcomes of a Phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer","volume":"116","author":"Silberstein","year":"2015","journal-title":"BJU Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.17650\/1726-9776-2020-16-1-54-63","article-title":"Oncological results of neoadjuvant chemohormonal therapy in patients with high and very high-risk prostate cancer","volume":"16","author":"Berkut","year":"2020","journal-title":"Cancer Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24134","article-title":"Impact of therapy on cancer metabolism in high\u2010risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy","volume":"81","author":"Qu","year":"2021","journal-title":"Prostate"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.07.009","article-title":"Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: a retrospective comparative study","volume":"37","author":"Pan","year":"2019","journal-title":"Urol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1160-8","article-title":"Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution","volume":"22","author":"Fujita","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-04268-2","article-title":"Efficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group)","volume":"57","author":"Yokoyama","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/life13051072","article-title":"Efficacy and safety of neoadjuvant luteinizing hormone-releasing hormone antagonist and tegafur-uracil chemohormonal therapy for high-risk prostate cancer","volume":"13","author":"Sugino","year":"2023","journal-title":"Life (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1038\/s41598-023-30627-7","article-title":"Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy","volume":"13","author":"Oishi","year":"2023","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.09.019","article-title":"Radical prostatectomy with and without neoadjuvant chemohormonal pretreatment for high-risk localized prostate cancer: a comparative propensity score matched analysis","volume":"17","author":"Narita","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67101-2","article-title":"Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)","volume":"366","author":"Bolla","year":"2005","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.024","article-title":"Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)","volume":"41","author":"Collette","year":"2005","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2008.02.008","article-title":"Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies","volume":"20","author":"Hudson","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3368","article-title":"Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy","volume":"6","author":"Santer","year":"2015","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24392","article-title":"Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials","volume":"115","author":"Bria","year":"2009","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2217\/FON-2022-1114","article-title":"Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis","volume":"22","author":"Jiang","year":"2026","journal-title":"Future Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.01.010","article-title":"Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis","volume":"12","author":"Petrelli","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108704","article-title":"Salvage lymphadenectomy or radiation therapy in prostate cancer patients with biochemical recurrence and PET positive lymph nodes after radical prostatectomy: a systematic review and pooled analysis","volume":"50","author":"Yang","year":"2024","journal-title":"Eur J Surg Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1693222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:14:29Z","timestamp":1776658469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1693222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1693222"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1693222","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1693222"}}